Sotorasib Tackles KRAS G12C-Mutated Pancreatic Cancer
Open accessAbstract
The KRASG12C inhibitor sotorasib was associated with a 21.1% objective response rate and an 84.2% disease control rate among patients who had already received at least one therapy for pancreatic ductal adenocarcinoma. These data come from the phase I/II CodeBreaK100 trial.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Cited by
Sorted by citations
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
- Venue
- Cancer Discovery
- Published
- 2022-04-01
- Volume
- 12
- Issue
- 4
- Pages
- 878-879
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4225354648
- Cited by
- 10
- References
- 0
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 4 · 2022: 3
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- sotorasib, KRAS G12C, pancreatic ductal adenocarcinoma, KRAS inhibitors, targeted therapy, objective response rate, disease control rate, advanced pancreatic cancer
- MeSH terms
- Humans, Pancreatic Neoplasms, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
